In insulin-naive adults with T2D, once-weekly icodec plus semaglutide vs insulin glargine U100 showed superior glycemic control and weight loss.

The FDA has approved Enspryng (satralizumab-mwge) for thyroid eye disease in adults, offering the first at-home subcutaneous IL-6 receptor antagonist for TED.

The amylin-based analog petrelintide achieves meaningful weight reduction for adults with obesity, according to a study.

For adults taking potassium-raising medications, greater consumption of dietary potassium as part of a DASH diet is not associated with hyperkalemia.

Robert Kauffman, MD, discusses the updated ACOG clinical guidance outlining pharmacologic and nonpharmacologic interventions for menopausal symptoms.

A pooled analysis of phase 3 ICONIC data demonstrates that concomitant GLP-1 medication use does not alter skin clearance, ...

Researchers evaluated the incidence and risk factors for ketoacidosis among adults with type 2 diabetes receiving treatment with SGLT2 inhibitors.

While lower-frequency IET may be sufficient to maintain BP reductions over the short term, higher frequencies are required to preserve the full CV benefits.

GLP-1 RAs outperformed mineralocorticoid receptor antagonists (MRAs) in cardiovascular protection in resistant hypertension and obesity.

Despite higher costs, Medicare Advantage does not improve glycemic control or health-related social needs in patients with type 2 diabetes.

Robotic surgery does not improve outcomes in total hip or knee replacement when compared with conventional surgery.

Low-dose radiotherapy (LDRT) offers multiple benefits in early knee osteoarthritis (OA), according to a study.